SK59193A3 - Pharmaceutical compositions for the treatment of b-cell malignancies - Google Patents

Pharmaceutical compositions for the treatment of b-cell malignancies Download PDF

Info

Publication number
SK59193A3
SK59193A3 SK591-93A SK59193A SK59193A3 SK 59193 A3 SK59193 A3 SK 59193A3 SK 59193 A SK59193 A SK 59193A SK 59193 A3 SK59193 A3 SK 59193A3
Authority
SK
Slovakia
Prior art keywords
cells
cell
malignant
cell malignancy
inhibiting
Prior art date
Application number
SK591-93A
Other languages
English (en)
Slovak (sk)
Inventor
Jacques Banchereau
France Thierry De
Original Assignee
Schering Plough Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Corp filed Critical Schering Plough Corp
Publication of SK59193A3 publication Critical patent/SK59193A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
SK591-93A 1990-12-13 1991-12-10 Pharmaceutical compositions for the treatment of b-cell malignancies SK59193A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90403585A EP0490006B1 (en) 1990-12-13 1990-12-13 Pharmaceutical compositions for the treatment of B-cell malignancies
PCT/EP1991/002380 WO1992010201A1 (en) 1990-12-13 1991-12-10 Pharmaceutical compositions for the treatment of b-cell malignancies

Publications (1)

Publication Number Publication Date
SK59193A3 true SK59193A3 (en) 1994-01-12

Family

ID=8205785

Family Applications (1)

Application Number Title Priority Date Filing Date
SK591-93A SK59193A3 (en) 1990-12-13 1991-12-10 Pharmaceutical compositions for the treatment of b-cell malignancies

Country Status (16)

Country Link
EP (2) EP0490006B1 (cs)
JP (1) JPH06504767A (cs)
AT (1) ATE135232T1 (cs)
AU (1) AU9072191A (cs)
CA (1) CA2098509A1 (cs)
CZ (1) CZ113593A3 (cs)
DE (1) DE69117974T2 (cs)
DK (1) DK0561927T3 (cs)
ES (1) ES2084995T3 (cs)
FI (1) FI932650A0 (cs)
GR (1) GR3019699T3 (cs)
HU (1) HU210009B (cs)
IE (1) IE64157B1 (cs)
OA (1) OA09788A (cs)
SK (1) SK59193A3 (cs)
WO (1) WO1992010201A1 (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ38095A3 (en) * 1992-08-19 1995-12-13 Schering Corp Pharmaceutical preparation for treating hiv infection, process of its preparation, il-4 and its use
US5679338A (en) * 1994-05-12 1997-10-21 Osteoarthritis Science, Inc. Use of IL-4 for inhibition of the breakdown of articular cartilage and other tissues
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004044A1 (en) * 1990-09-06 1992-03-19 Schering Corporation Use of il-4 to treat solid tumors

Also Published As

Publication number Publication date
CZ113593A3 (en) 1994-01-19
DK0561927T3 (da) 1996-07-29
EP0490006B1 (en) 1994-06-22
AU9072191A (en) 1992-07-08
JPH06504767A (ja) 1994-06-02
IE64157B1 (en) 1995-07-12
HU210009B (en) 1995-01-30
DE69117974D1 (de) 1996-04-18
ES2084995T3 (es) 1996-05-16
FI932650A7 (fi) 1993-06-10
WO1992010201A1 (en) 1992-06-25
EP0561927B1 (en) 1996-03-13
CA2098509A1 (en) 1992-06-14
EP0561927A1 (en) 1993-09-29
FI932650L (fi) 1993-06-10
IE914328A1 (en) 1992-06-17
GR3019699T3 (en) 1996-07-31
FI932650A0 (fi) 1993-06-10
HU9301719D0 (en) 1993-09-28
DE69117974T2 (de) 1996-07-25
ATE135232T1 (de) 1996-03-15
HUT64478A (en) 1994-01-28
OA09788A (en) 1994-04-15
EP0490006A1 (en) 1992-06-17

Similar Documents

Publication Publication Date Title
CN105008521B (zh) 调节干细胞的免疫调节作用的方法
JP4416839B2 (ja) 二次性免疫不全症の治療法
CA2087525C (en) Adoptive immunotherapy with interleukin-7
CA2181568C (en) Use of interleukin-12 to prevent graft versus host disease
AU661979B2 (en) Use of IL-4 to treat solid tumors
Mastino et al. Combination therapy with thymosin α1 potentiates the anti‐tumor activity of interleukin‐2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice
KR101192136B1 (ko) 혈액 줄기 세포의 동원에 유효한 ｇ-ｃｓｆ와 ｐｌｇｆ의조합 약제
Barbano et al. Anti-lymphocyte globulin stimulates normal human T cells to proliferate and to release lymphokines in vitro. A study at the clonal level
SK59193A3 (en) Pharmaceutical compositions for the treatment of b-cell malignancies
EP0684828A1 (en) EXPANSION OF STEM CELLS IN LONG TERM BONE MARROW CULTURES BY NEUTRALIZATION OF TGF-$g(b)
AU712606B2 (en) Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
US6022536A (en) Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
Sunderland et al. Interleukin-3: Its biology and potential uses in pediatric hematology/oncology
Cicco et al. Cytokines in the pathogenesis and management of Non-Hodgkin’s Lymphomas
EP0831887B1 (en) Therapy using lymphotoxin and thrombopoietin
CHARAK et al. Augmentation of murine hematopoiesis by interleukin 2-activated irradiated T cells
Moore Regulatory Defects in Leukemia: In Vitro Analysis
HK1217211B (zh) 调节干细胞的免疫调节作用的方法